Acute Myocardial Infarction
Approximately 800,000 events of acute myocardial infarction occur in the US each year and, despite all of the advances in medicine and intervention, about 20% or approximately 160,000 patients have a ST-Elevation MI (STEMI) resulting in a reduced Left Ventricular Ejection Fraction (LVEF) of less than 50%. That means that their MI was big enough and their heart so damaged that the remaining heart muscle could not compensate for the damaged heart tissues and, over time, the hearts starts to fail. These patients are at significant risk of downstream adverse events including congestive heart failure, re-current MI, significant arrhythmias, premature death or acute coronary syndrome, and are the target population for AMR-001. This population represents an accessible market of over $1.2 billion annually for AMR–001.
• Improve microvascular density (perfusion) to rescue at-risk cardiomyocytes from hibernation and apoptosis
• Preserve heart muscle function
• Prevent downstream MACE
• Improve QOL & longevity
Pharmacoeconomic impact:
• Adverse left ventricular remodeling after STEMI can result in an average medical burden of greater than or equal to $30K to $80K per patient, per year of life
• If the patients LVEF declines below 40%, then the cost per year escalates for the balance of the patient’s lifetime - AMR-001 is designed to prevent this decline
• AMR-001 is designed to prevent a decline in LVEF, thereby limiting adverse left ventricular remodeling and its negative consequences
• Pricing will allow strong commercial margins while significantly reducing costs to the health care system